Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;10(4):441-51.
doi: 10.1586/erp.10.49.

Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes

Elizabeth B Hirsch  1 , Vincent H Tam
Affiliations
Review

Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes

Elizabeth B Hirsch et al. Expert Rev Pharmacoecon Outcomes Res. 2010 Aug.

Abstract

Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no international consensus on the definition of multidrug resistance exists, making direct comparison of the literature difficult. Inappropriate empirical therapy has been associated with increased mortality in P. aeruginosa infections; delays in starting appropriate therapy may contribute to increased length of hospital stay and persistence of infection. In addition, worse clinical outcomes may be associated with MDR infections owing to limited effective antimicrobial options. This article aims to summarize the contemporary literature on patient outcomes following infections caused by drug-resistant P. aeruginosa. The impact of antimicrobial therapy on patient outcomes, mortality and morbidity; and the economic impact of MDR P. aeruginosa infections will be examined.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Factors challenging and supporting the argument that multidrug-resistant pathogens are associated with worse clinical outcomes.
See this image and copyright information in PMC

References

    1. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch. Intern. Med. 1985;145(9):1621–1629. - PubMed
    1. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch. Intern. Med. 2000;160(4):501–509. - PubMed

    1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis. 2005;41(6):848–854. •• Data from National Nosocomial Infections Surveillance System (1986–2003) showing trends in nosocomial infections and resistance rates in Gram-negative organisms.

    1. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control. 2004;32(8):470–485. - PubMed
    1. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 2004;48(12):4606–4610. - PMC - PubMed

Publication types

MeSH terms

Substances